[en] Sustained, targeted, high-level transgene expression in primary B lymphocytes may be useful for gene therapy in B cell disorders. We developed several candidate B-lineage predominant self-inactivating lentiviral vectors (LC) containing alternative enhancer/promoter elements including : the immunoglobulin β (Igβ) promoter combined with the immunoglobulin µ enhancer (EµB29); and the endogenous BTK promoter with or without Eµ (EµBtkp or Btkp). LV-driven enhanced green fluorescent protein (eGFP) reporter expression was evaluated in cell lines and primary cells derived from human or murine hematopoietic stem cells (HSC). In murine primary cells, eµB29 and EµBtkp LV-mediated high-level expression in immature and mature B cells compared with all other lineages. Expression increased with B cell maturation and was maintained in peripheral subsets. Expression in T and myeloid cells was much lower in percentage and intensity. Similarly, both EµB29 and EµBtkp LV exhibited high-level activity in human primary B cells. In contrast to EµB29, Btkp and EµBtkp LV also exhibited modest actiity in myeloid cells, consistent with the expression profile of endogenous Bruton's tyrosine kinase (Btk). Notably, EµB29 end EµBtkp activity was superior in all expression models to an alternative, B-lineage targeted vector containing the EµS.CD19 enhancer/promoter. In summary, EµB29 and EµBtkp LV comprise efficient delivery platforms for gene expression in B-lineage cells.
Gaspar, HB, Howe, S and Thrasher, AJ (2003). Gene therapy progress and prospects: gene therapy for severe combined immunodefciency. Gene Ther 10: 1999-2004. (Pubitemid 37407095)
Tsukada, S, Saffran, DC, Rawlings, DJ, Parolini, O, Allen, RC, Klisak, I et al. (1993). Defcient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 72: 279-290. (Pubitemid 23044942)
Smith, C and Witte, ON (1999). Functional aspects of Btk signaling in Primary Immunodefciency Diseases, a Molecular and Genetic Approach. Oxford University Press.
Moreau, T, Calmels, B, Barlogis, V, Michel, G, Tonnelle, C and Chabannon, C (2007). Potential application of gene therapy to X-linked agammaglobulinemia. Curr Gene Ther 7: 284-294. (Pubitemid 47232959)
Yu, PW, Tabuchi, RS, Kato, RM, Astrakhan, A, Humblet-Baron, S, Kipp, K et al. (2004). Sustained correction of B-cell development and function in a murine model of X-linked agammaglobulinemia (XLA) using retroviral-mediated gene transfer. Blood 104: 1281-1290. (Pubitemid 39166501)
Uchida, N, Sutton, RE, Friera, AM, He, D, Reitsma, MJ, Chang, WC et al. (1998). HIV, but not murine leukemia virus, vectors mediate high effciency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells. Proc Natl Acad Sci USA 95: 11939-11944. (Pubitemid 28460518)
Case, SS, Price, MA, Jordan, CT, Yu, XJ, Wang, L, Bauer, G et al. (1999). Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci USA 96: 2988-2993. (Pubitemid 29148831)
Naldini, L, Blömer, U, Gage, FH, Trono, D and Verma, IM (1996). Effcient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 93: 11382-11388. (Pubitemid 26347130)
Zufferey, R, Dull, T, Mandel, RJ, Bukovsky, A, Quiroz, D, Naldini, L et al. (1998). Self-inactivating lentivirus vector for safe and effcient in vivo gene delivery. J Virol 72: 9873-9880. (Pubitemid 28520853)
Schröder, AR, Shinn, P, Chen, H, Berry, C, Ecker, JR and Bushman, F (2002). HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110: 521-529. (Pubitemid 35232295)
Hacein-Bey-Abina, S, von Kalle, C, Schmidt, M, Le Deist, F, Wulffraat, N, McIntyre, E et al. (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunodefciency. N Engl J Med 348: 255-256. (Pubitemid 36077924)
Howe, SJ, Mansour, MR, Schwarzwaelder, K, Bartholomae, C, Hubank, M, Kempski, H et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118: 3143-3150.
Rivella, S, May, C, Chadburn, A, Rivière, I and Sadelain, M (2003). A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human β-globin gene transfer. Blood 101: 2932-2939. (Pubitemid 36857977)
Cartier, N, Hacein-Bey-Abina, S, Bartholomae, CC, Veres, G, Schmidt, M, Kutschera, I et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326: 818-823.
Pawliuk, R, Westerman, KA, Fabry, ME, Payen, E, Tighe, R, Bouhassira, EE et al. (2001). Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 294: 2368-2371. (Pubitemid 33140563)
Indraccolo, S, Minuzzo, S, Roccaforte, F, Zamarchi, R, Habeler, W, Stievano, L et al. (2001). Effects of CD2 locus control region sequences on gene expression by retroviral and lentiviral vectors. Blood 98: 3607-3617.
Cui, Y, Golob, J, Kelleher, E, Ye, Z, Pardoll, D and Cheng, L (2002). Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells. Blood 99: 399-408. (Pubitemid 34533073)
Gough, PJ and Raines, EW (2003). Gene therapy of apolipoprotein E-defcient mice using a novel macrophage-specifc retroviral vector. Blood 101: 485-491. (Pubitemid 36077569)
Moreau, T, Bardin, F, Imbert, J, Chabannon, C and Tonnelle, C (2004). Restriction of transgene expression to the B-lymphoid progeny of human lentivirally transduced CD34+ cells. Mol Ther 10: 45-56. (Pubitemid 38878148)
Lutzko, C, Senadheera, D, Skelton, D, Petersen, D and Kohn, DB (2003). Lentivirus vectors incorporating the immunoglobulin heavy chain enhancer and matrix attachment regions provide position-independent expression in B lymphocytes. J Virol 77: 7341-7351. (Pubitemid 36734502)
Moreau, T, Barlogis, V, Bardin, F, Nunes, JA, Calmels, B, Chabannon, C et al. (2008). Development of an enhanced B-specifc lentiviral vector expressing BTK: a tool for gene therapy of XLA. Gene Ther 15: 942-952. (Pubitemid 351791481)
Taher, TE, Tulone, C, Fatah, R, D'Acquisto, F, Gould, DJ and Mageed, RA (2008). Repopulation of B-lymphocytes with restricted gene expression using haematopoietic stem cells engineered with lentiviral vectors. Gene Ther 15: 998-1006. (Pubitemid 351865756)
Faust, EA, Rawlings, DJ, Saffran, DC and Witte, ON (1995). Development of btk transgenic mice. Curr Top Microbiol Immunol 194: 363-370. (Pubitemid 24369476)
Satterthwaite, AB, Cheroutre, H, Khan, WN, Sideras, P and Witte, ON (1997). Btk dosage determines sensitivity to B cell antigen receptor cross-linking. Proc Natl Acad Sci USA 94: 13152-13157.
Robbins, PB, Yu, XJ, Skelton, DM, Pepper, KA, Wasserman, RM, Zhu, L et al. (1997). Increased probability of expression from modifed retroviral vectors in embryonal stem cells and embryonal carcinoma cells. J Virol 71: 9466-9474. (Pubitemid 27492391)
Thompson, AA, Wood, WJ Jr, Gilly, MJ, Damore, MA, Omori, SA and Wall, R (1996). The promoter and 5' fanking sequences controlling human B29 gene expression. Blood 87: 666-673.
Banerji, J, Olson, L and Schaffner, W (1983). A lymphocyte-specifc cellular enhancer is located downstream of the joining region in immunoglobulin heavy chain genes. Cell 33: 729-740. (Pubitemid 13073988)
Hagman, J and Grosschedl, R (1994). Regulation of gene expression at early stages of B-cell differentiation. Curr Opin Immunol 6: 222-230. (Pubitemid 24106819)
Hermanson, GG, Eisenberg, D, Kincade, PW and Wall, R (1988). B29: a member of the immunoglobulin gene superfamily exclusively expressed on β-lineage cells. Proc Natl Acad Sci USA 85: 6890-6894.
Rohrer, J, Parolini, O, Belmont, JW, Conley, ME and Parolino O [corrected to Parolini, O (1994). The genomic structure of human BTK, the defective gene in X-linked agammaglobulinemia. Immunogenetics 40: 319-324. (Pubitemid 24299320)
Oeltjen, JC, Malley, TM, Muzny, DM, Miller, W, Gibbs, RA and Belmont, JW (1997). Large-scale comparative sequence analysis of the human and murine Bruton's tyrosine kinase loci reveals conserved regulatory domains. Genome Res 7: 315-329. (Pubitemid 27183000)
Müller, S, Sideras, P, Smith, CI and Xanthopoulos, KG (1996). Cell specifc expression of human Bruton's agammaglobulinemia tyrosine kinase gene (Btk) is regulated by Sp1- and Spi-1/PU.1-family members. Oncogene 13: 1955-1964. (Pubitemid 26397455)
Himmelmann, A, Thevenin, C, Harrison, K and Kehrl, JH (1996). Analysis of the Bruton's tyrosine kinase gene promoter reveals critical PU.1 and SP1 sites. Blood 87: 1036-1044. (Pubitemid 26049874)
Rohrer, J and Conley, ME (1998). Transcriptional regulatory elements within the frst intron of Bruton's tyrosine kinase. Blood 91: 214-221. (Pubitemid 28018747)
Yu, L, Mohamed, AJ, Simonson, OE, Vargas, L, Blomberg, KE, Björkstrand, B et al. (2008). Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-kappaB. Blood 111: 4617-4626.
Pillai, S, Cariappa, A and Moran, ST (2005). Marginal zone B cells. Annu Rev Immunol 23: 161-196. (Pubitemid 40563168)
Hiramatsu, H, Nishikomori, R, Heike, T, Ito, M, Kobayashi, K, Katamura, K et al. (2003). Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/γcnull mice model. Blood 102: 873-880. (Pubitemid 36917778)
Blom, B and Spits, H (2006). Development of human lymphoid cells. Annu Rev Immunol 24: 287-320.
Watanabe, Y, Takahashi, T, Okajima, A, Shiokawa, M, Ishii, N, Katano, I et al. (2009). The analysis of the functions of human B and T cells in humanized NOD/shi-scid/ γc(null) (NOG) mice (hu-HSC NOG mice). Int Immunol 21: 843-858.
Nienhuis, AW, Dunbar, CE and Sorrentino, BP (2006). Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther 13: 1031-1049. (Pubitemid 43779188)
Klug, CA, Cheshier, S and Weissman, IL (2000). Inactivation of a GFP retrovirus occurs at multiple levels in long-term repopulating stem cells and their differentiated progeny. Blood 96: 894-901. (Pubitemid 30616853)
Kerns, HM, Ryu, BY, Stirling, BV, Sather, BD, Astrakhan, A, Humblet-Baron, S et al. (2010). B cell-specifc lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia. Blood 115: 2146-2155.
Plebani, A, Soresina, A, Rondelli, R, Amato, GM, Azzari, C, Cardinale, F et al.; Italian Pediatric Group for XLA-AIEOP. (2002). Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol 104: 221-230.
O'Neill, LA (2008). When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction. Immunity 29: 12-20. (Pubitemid 351952460)
Jefferies, CA and O'Neill, LA (2004). Bruton's tyrosine kinase (Btk)-the critical tyrosine kinase in LPS signalling? Immunol Lett 92: 15-22. (Pubitemid 38470045)
Jefferies, CA, Doyle, S, Brunner, C, Dunne, A, Brint, E, Wietek, C et al. (2003). Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4. J Biol Chem 278: 26258-26264. (Pubitemid 36835395)
Ryu, BY, Evans-Galea, MV, Gray, JT, Bodine, DM, Persons, DA and Nienhuis, AW (2008). An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation. Blood 111: 1866-1875. (Pubitemid 351451495)
Modlich, U, Navarro, S, Zychlinski, D, Maetzig, T, Knoess, S, Brugman, MH et al. (2009). Insertional transformation of hematopoietic cells by self-inactivating lentiviral and γ retroviral vectors. Mol Ther 17: 1919-1928.
Halene, S, Wang, L, Cooper, RM, Bockstoce, DC, Robbins, PB and Kohn, DB (1999). Improved expression in hematopoietic and lymphoid cells in mice after transplantation of bone marrow transduced with a modifed retroviral vector. Blood 94: 3349-3357. (Pubitemid 29536128)
